WO2019052165A1 - 蝉花子实体的新用途 - Google Patents

蝉花子实体的新用途 Download PDF

Info

Publication number
WO2019052165A1
WO2019052165A1 PCT/CN2018/082483 CN2018082483W WO2019052165A1 WO 2019052165 A1 WO2019052165 A1 WO 2019052165A1 CN 2018082483 W CN2018082483 W CN 2018082483W WO 2019052165 A1 WO2019052165 A1 WO 2019052165A1
Authority
WO
WIPO (PCT)
Prior art keywords
gout
fruit body
extraction
flowering
medicament
Prior art date
Application number
PCT/CN2018/082483
Other languages
English (en)
French (fr)
Inventor
闫文娟
刘艳菊
孙长胜
Original Assignee
浙江泛亚生物医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江泛亚生物医药股份有限公司 filed Critical 浙江泛亚生物医药股份有限公司
Publication of WO2019052165A1 publication Critical patent/WO2019052165A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A61K36/068—Cordyceps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Definitions

  • the invention relates to a new use of the scorpion fruit body, in particular to the new use of the scorpion fruit body in the treatment of gout and uric acid.
  • the scorpion fruit body obtained by artificial cultivation is a fungal microbial material, and has high nutritional value in addition to specific medicinal effects. Thistle is rich in protein, amino acids, cellulose, fatty acids, multivitamins, trace elements and sugars.
  • One aspect of the present invention provides the use of an artificially cultured scorpion fruit body for the preparation of a medicament for treating gout.
  • the gout includes acute gout and chronic gout.
  • the flowering fruit body is used for preparing a medicament for treating tubular degeneration, necrosis, tubular dilatation, and urate deposition.
  • the flowering fruit body may be a powder obtained by directly pulverizing the scorpion fruit body, or may be an extract obtained by extracting the scorpion fruit body by a conventional solvent, or may be an effective part prepared by further purifying and purifying the extract.
  • the conventional solvent includes water, 20% to 95% ethanol solution;
  • the extraction method includes any one of immersion extraction, ultrasonic extraction, reflux extraction, decoction extraction, microwave extraction, and percolation extraction;
  • the purification and purification process Including various column chromatography, such as macroporous resin column, gel column and so on.
  • a second aspect of the invention provides a pharmaceutical composition comprising an effective amount of a flowering body entity and a pharmaceutically acceptable adjuvant.
  • an “effective amount” of an ingredient refers to an amount of the ingredient that is effective to provide the desired effect when used in combination with other ingredients.
  • the “effective amount” will vary from subject to subject, depending on the age and general condition of the individual, the particular active drug, and the like. Thus, it is not always possible to refer to an accurate “effective amount”, however, a suitable “effective amount” in any individual case can be determined by one of ordinary skill in the art using routine experimental methods.
  • the flowering fruit body may be a powder obtained by directly pulverizing the scorpion fruit body, or may be an extract obtained by extracting the scorpion fruit body by a conventional solvent, or may be an effective part prepared by further purifying and purifying the extract.
  • the conventional solvent includes water, 20% to 95% ethanol solution;
  • the extraction method includes any one of immersion extraction, ultrasonic extraction, reflux extraction, decoction extraction, microwave extraction, and percolation extraction;
  • the purification and purification process Including various column chromatography, such as macroporous resin column, gel column and so on.
  • the pharmaceutical composition includes a capsule, a tablet, a granule, a gel, a sustained release, an oral solution, a pill or a nano preparation.
  • the pharmaceutically acceptable excipients include fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, matrices, and the like.
  • Filling agents include: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.; disintegrating agents include: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, Cross-linked polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, croscarmellose sodium, etc.; lubricants include: magnesium stearate, sodium lauryl sulfate, talc, silica, etc.; suspending agent Including: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, etc.; binders include starch pulp, polyvinylpyrrolidone, hydroxypropyl methylcellulose, and the like.
  • the amount of the flowering fruit body used in the present invention is 5-30 times higher than the recommended amount of the human body (0.017 g/kg), the gout and the uric acid lowering effect are treated to different degrees.
  • Figure 1 is a 100-fold pathological picture of renal HE staining
  • Table 3-4 The results are shown in Table 3-4.
  • Table 1 shows the results of acute gout test: compared with the blank control group, the serum uric acid value of the model control group increased, there was a statistical difference (P ⁇ 0.05). Compared with the model control group, the uric acid decreased in the positive control group and the high dose group of sputum pollen, which was statistically significant (P ⁇ 0.05).
  • Table 2 The results of chronic gout test showed that there was a statistically significant difference in serum uric acid between the model control group and the control group (P ⁇ 0.05). Compared with the model control group, the serum uric acid value of the positive control group and the scutellariae group decreased, which was statistically significant (P ⁇ 0.05).
  • Rat model of chronic gout and each administration group were intragastrically administered with adenine and ethambutol hydrochloride every day, and the corresponding dose of liquid was administered for 21 days. 1.5 hours after the last administration, the left kidney and part of the right kidney were fixed, and urate crystal staining and HE staining were performed respectively.
  • the recommended daily dosage of the body of the scorpion scorpion is 0.017g/kg body weight
  • the clinical dose of the positive control drug other sterol tablets (manufacturer: Chongqing Qingyang Pharmaceutical Co., Ltd., batch number: 150403) is 300mg/d.
  • the experimental dose of acute gout is 10, 20, 30 times of the clinical dose of the human body as the low, medium and high dose group
  • the experimental dose of chronic gout is 5, 10, 20 times of the clinical dose of the human body as the low, medium and High-dose group
  • 20 times and 10 times of clinical doses of human body were used as design doses for positive and chronic gout test positive control drugs (Same Table 2).
  • the liver index results are shown in Table 5. The results showed that compared with the model control group, the liver index of the blank control group and the high dose group of the scutellariae were increased, which was statistically significant (P ⁇ 0.01).
  • Figure 1 is a 100-fold pathological picture of HE staining.
  • the tissue structure of the blank control group in Figure 1A was not abnormal.
  • the kidney of the model control group in Figure 1B showed a large number of renal tubular epithelial cell degeneration, necrosis, renal tubular urate deposition, tubular dilatation, and partial renal tubular inflammatory cell infiltration.
  • a small amount of renal tubules were seen in the cell cast type, which was consistent with the gout model lesions in rats; Figure 1C.
  • the positive control group showed a certain degree of repair in the kidneys of the experimental animals. Renal tubular degeneration, necrosis, tubular dilatation, urate deposition and other lesions were all significantly improved.
  • Figure 2 is a 100-fold pathological picture of kidney Gomori-type hexamine silver staining.
  • Fig. 2A there was no black crystalline substance in the blank control group; in Fig. 2B, the control group showed a large amount of black crystalline material in the renal tubule; in Fig. 2C, the positive control group showed a small amount of black crystalline material in the renal tubule;
  • Fig. 2D-F is ⁇ In the low, medium and high dose groups of the fruiting body, the black kidneys were found in a large number of renal tubules in the low dose group. The above lesions in the middle and high dose groups showed different degrees of improvement, and the degree of improvement was related to the dose.
  • safflower fruit body powder Take 10g of safflower fruit body powder, add suitable excipients to tablets (including controlled release tablets, matrix tablets, coated tablets, dispersible tablets, etc.), according to tablets (including controlled release tablets, matrix tablets, coated tablets, dispersible tablets) The process is prepared into tablets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

人工蝉花子实体在制备治疗痛风或降尿酸药物中的用途。所述人工蝉花子实体，对急、慢性痛风均有一定改善作用，可用于制备治疗痛风及降尿酸的药物。

Description

蝉花子实体的新用途 技术领域
本发明涉及蝉花子实体的新用途，尤其是蝉花子实体在治疗痛风及降尿酸方面的新用途。
背景技术
当人体内嘌呤物质的新陈代谢发生紊乱或尿酸的排泄出现障碍，就会造成高尿酸血症，当人体血尿酸浓度过高时，机体内尿酸以钠盐的形式沉积在关节、软骨和肾脏中，引起组织异物炎性反应，即形成痛风。现在，由于人们的生活、饮食习惯的改变，痛风的发病率逐渐上升。反复的发病，关节的发炎、肿大、变形等给患者带来了极大的痛苦。而在治疗上，临床中常用的几种西药，不良反应比较明显，如常见的恶心、呕吐、腹泻等，严重的可造成肝肾脏功能的损害等并发症，患者的耐受性逐渐降低，进而对药物治疗产生排斥心理。故痛风及高尿酸的治疗迫在眉睫，研发出治疗效果好、无毒副作用、患者易接受的天然或生物药物意义重大。
通过人工培育获得的蝉花子实体，属真菌类微生物原料，除具有特定的药效外，还具有较高的营养价值。蝉花中含有丰富的蛋白质、氨基酸、纤维素、脂肪酸、多种维生素、微量元素及糖类。
发明内容
本发明的目的在于提供蝉花子实体在治疗痛风及降尿酸方面的新用途。
本发明的一个方面提供人工培养的蝉花子实体在制备治疗痛风的药物中的应用。
进一步，所述痛风包括急性痛风和慢性痛风。
进一步，所述蝉花子实体在制备具有降尿酸作用的药物中的应用。
进一步，所述蝉花子实体在制备治疗痛风引起的肾脏和/或肝脏损害的药物中的应用。
进一步，所述蝉花子实体在制备治疗痛风引起肾小管病变的药物中的应 用。
进一步，所述蝉花子实体在制备治疗肾小管变性、坏死、肾小管扩张、尿酸盐沉积药物中的应用。
进一步，所述蝉花子实体可以是蝉花子实体直接粉碎获得的粉末，也可以是蝉花子实体经常规溶剂提取得到的提取物，还可以是提取物经过进一步精制纯化工艺制备得到的有效部位。
所述常规溶剂包括水、20％～95％乙醇溶液；所述提取方法包括浸渍提取、超声提取、回流提取、煎煮提取、微波提取、渗漉提取中的任意一种；所述精制纯化工艺包括各类柱色谱，如大孔树脂柱、凝胶柱等。
本发明的第二方面提供一种药物组合物，包含有效量的蝉花子实体和药学上可接受的辅料。
本发明所述的“有效量”是指无毒性，但足够量的提供所需的作用的药物或药剂。在本发明的药物组合物中，一种成分的“有效量”是指该成分在和其他成分联合应用时有效提供所需效应的量。“有效量”会因受试者的不同而不同，依据年龄和个体的一般情况，特定的活性药物等等。因此，不可能总是指精确的“有效量”，然而，任何个体病例中合适的“有效量”可以由本领域普通技术人员应用常规的实验方法来测定。
所述蝉花子实体可以是蝉花子实体直接粉碎获得的粉末，也可以是蝉花子实体经常规溶剂提取得到的提取物，还可以是提取物经过进一步精制纯化工艺制备得到的有效部位。
所述常规溶剂包括水、20％～95％乙醇溶液；所述提取方法包括浸渍提取、超声提取、回流提取、煎煮提取、微波提取、渗漉提取中的任意一种；所述精制纯化工艺包括各类柱色谱，如大孔树脂柱、凝胶柱等。
所述药物组合物包括胶囊剂、片剂、颗粒剂、凝胶剂、缓释剂、口服液、滴丸剂或纳米制剂。所述药学上可接受的辅料包括填充剂、崩解剂、润滑剂、助悬剂、粘合剂、甜味剂、矫味剂、防腐剂、基质等。填充剂包括：淀粉、预胶化淀粉、乳糖、甘露醇、甲壳素、微晶纤维素、蔗糖等；崩解剂包括：淀粉、预胶化淀粉、微晶纤维素、羧甲基淀粉钠、交联聚乙烯吡咯烷酮、低取代羟丙纤维素、交联羧甲基纤维素钠等；润滑剂包括：硬脂酸镁、十二烷 基硫酸钠、滑石粉、二氧化硅等；助悬剂包括：聚乙烯吡咯烷酮、微晶纤维素、蔗糖、琼脂、羟丙基甲基纤维素等；粘合剂包括，淀粉浆、聚乙烯吡咯烷酮、羟丙基甲基纤维素等。
本发明中的蝉花子实体的使用量相当于人体推荐量(0.017g/kg)5-30倍时，均有不同程度的治疗痛风及降尿酸作用。
附图说明
图1为肾脏HE染色100倍病理图片
A：空白对照组；B：模型对照组；C：阳性对照组；D：蝉花子实体低剂量组；E：蝉花子实体中剂量组；F：蝉花子实体高剂量组。
图2为肾脏Gomori式六胺银法染色100倍病理图片
A：空白对照组；B：模型对照组；C：阳性对照组；D：蝉花子实体低剂量组；E：蝉花子实体中剂量组；F：蝉花子实体高剂量组。
具体实施方式
以下实施例中所用蝉花菌种保藏于中国微生物菌种保藏管理委员会普通微生物中心，保藏号CGMCC No 3453(该菌种已在申请号为201110120603.1的发明专利中公开，为已知菌种)，粉碎直接药用；经野生蝉花系统选育而成的蝉花子实体也可以实现本发明的效果，蝉花菌种类型并不构成影响本发明效果的因素。
实施例1蝉花子实体在降尿酸方面的作用
1.1模型建立：急性痛风模型小鼠各给药组灌胃相应剂量药液7天，于末次给药前30min，模型及各给药组腹腔注射次黄嘌呤及皮下注射氧嗪酸钾造模。末次给药1.5h，动物采血检测尿酸。
慢性痛风大鼠模型及各给药组每天灌胃腺嘌呤及乙胺丁醇盐酸盐造模，同时灌胃相应剂量药液21天。末次给药后1.5h，采血检测尿酸。
1.2分组方法：急、慢性痛风实验均随机分为空白对照组，模型对照组，阳性对照组、蝉花子实体低、中、高剂量组，10只/组，共6组。
1.3剂量设计：蝉花子实体人体日推荐用量为0.017g/kg体重，阳性对 照药别嘌呤醇片(厂家：重庆青阳药业有限公司，批号：150403)的人体临床用量为300mg/d。按成人体重60kg计算，急性痛风实验剂量以人体临床用量的10、20、30倍作为低、中、高剂量组；慢性痛风实验剂量以人体临床用量的5、10、20倍作为低、中、高剂量组；分别以人体临床用量的20倍、10倍作为急、慢性痛风实验阳性对照药的设计剂量。
表1 急性痛风实验剂量设计与分组情况表
Figure PCTCN2018082483-appb-000001
表2 慢性痛风实验剂量设计与分组情况表
Figure PCTCN2018082483-appb-000002
注：按成人体重60kg计算。
1.4实验结果:
结果见表3-4。表1急性痛风实验结果表明：与空白对照组相比，模型对照组血清尿酸值升高、有统计学差异(P<0.05)。与模型对照组相比，阳性对照组、蝉花粉高剂量组尿酸下降，有统计学差异(P<0.05)。表2慢性痛风实验结果表明：与空白对照组相比，模型对照组血清尿酸升高有统计学差异(P<0.05)。与模型对照组相比，阳性对照组、蝉花子实体各剂量组血清尿酸值下降，有统计学差异(P<0.05)。
表3 急性痛风实验各组动物尿酸结果
Figure PCTCN2018082483-appb-000003
组别 n 剂量 尿酸(μmol/L)
空白对照组 10 — 137.8±28.6
模型对照组 10 — 168.1±26.8 ▲
阳性对照组 10 100mg/kg 25.8±21.3 **
蝉花子实体低剂量组 10 0.17g/kg 168.9±17.8
蝉花子实体中剂量组 10 0.34g/kg 164.4±34.6
蝉花子实体高剂量组 10 0.51mg/kg 142.6±35.4 *
注：与空白对照组比较，“▲”P<0.05，“▲▲”P<0.01；与模型对照组比较，“*”P<0.05，“**”P<0.01。
表4 慢性痛风实验各组动物尿酸结果
Figure PCTCN2018082483-appb-000004
组别 n 剂量 尿酸(μmol/L)
空白对照组 10 — 87.5±26.8
模型对照组 10 — 144.2±60.2▲▲
阳性对照组 10 50mg/kg 99.7±26.4**
蝉花子实体低剂量组 10 0.085g/kg 106.7±19.8*
蝉花子实体中剂量组 10 0.17g/kg 108.9±30.5*
蝉花子实体高剂量组 10 0.34g/kg 89.5±15.4**
注：与空白对照组比较，“▲”P＜0.05，“▲▲”P＜0.01；与模型对照组比较，“*”P＜0.05，“**”P＜0.01。
结果表明，蝉花子实体对急、慢性痛风均有一定的降尿酸作用。
实施例2蝉花子实体在慢性痛风中对肝脏肾脏的影响
2.1模型建立：慢性痛风大鼠模型及各给药组每天灌胃腺嘌呤及乙胺丁醇盐酸盐造模，同时灌胃相应剂量药液21天。末次给药后1.5h，固定左肾及部分右肾，分别作尿酸盐结晶染色及HE染色。
2.2分组方法：慢性痛风实验均随机分为空白对照组，模型对照组，阳性对照组、蝉花粉低、中、高剂量组，10只/组，共6组。
2.3剂量设计：蝉花子实体人体日推荐用量为0.017g/kg体重，阳性对照药别嘌呤醇片(厂家：重庆青阳药业有限公司，批号：150403)的人体临床用量为300mg/d。按成人体重60kg计算，急性痛风实验剂量以人体临床用量的10、20、30倍作为低、中、高剂量组；慢性痛风实验剂量以人体临床用量的5、10、20倍作为低、中、高剂量组；分别以人体临床用量的20倍、10倍作为急、慢性痛风实验阳性对照药的设计剂量(同表2)。
2.4实验结果：
肝脏指数结果见表5，结果表明，与模型对照组相比，空白对照组及蝉花子实体高剂量组肝脏指数升高，有统计学差异(P＜0.01)。
表5 慢性痛风实验各组动物肝脏评分结果
Figure PCTCN2018082483-appb-000005
组别 n 肝脏
空白对照组 10 4.30±0.30
模型对照组 10 4.06±0.27
阳性对照组 10 5.28±0.65**
蝉花子实体低剂量组 10 4.26±0.55
蝉花子实体中剂量组 10 4.18±0.32
蝉花子实体高剂量组 10 4.54±0.18**
注：与空白对照组相比，“▲”P<0.05，“▲▲”P<0.01；与模型对照组相比，“*”P<0.05，“**”P<0.01。
病理组织学检查结果见图1-2。
图1为HE染色100倍病理图片。图1A空白对照组肾脏组织结构未见 异常；图1B模型对照组动物肾脏主要表现为大量肾小管上皮细胞变性、坏死，肾小管尿酸盐沉积，肾小管扩张，部分肾小管见炎性细胞浸润，少量肾小管见细胞管型，符合大鼠痛风模型病变；图1C阳性对照组实验动物肾脏可见一定程度的修复，肾小管变性、坏死、肾小管扩张、尿酸盐沉积等病变均可见明显好转；图1D-F分别为蝉花子实体低、中、高剂量组，低剂量组肾脏组织病变与模型对照组病变未见明显差异，中、高剂量组上述病变可见不同程度的改善，改善程度与剂量存在相关性。
图2为肾脏Gomori式六胺银法染色100倍病理图片。图2A空白对照组肾脏未见黑色结晶物质；图2B模型对照组动物大量肾小管内可见黑色结晶物质；图2C阳性对照组实验动物少量肾小管内见黑色结晶物质；图2D-F分别为蝉花子实体低、中、高剂量组，低剂量组肾脏大量肾小管内见黑色结晶物质，中、高剂量组上述病变可见不同程度的改善，改善程度与剂量存在相关性。
结果表明，蝉花子实体对慢性痛风引起的肝肾方面的病变具有一定的改善作用。
实施例3
取蝉花子实体粉末10g，加入注射剂(包括冻干粉针剂和无菌分装干粉针剂)适当辅料，按注射剂(包括冻干粉针剂和无菌分装干粉针剂)工艺制备成注射剂。
实施例4
取蝉花子实体粉末10g，加入片剂(包括缓控释片、骨架片、包衣片、分散片等)适当辅料，按片剂(包括缓控释片、骨架片、包衣片、分散片等)工艺制备成片剂。
实施例5
取蝉花子实体粉末10g，加入胶囊剂适当辅料，按胶囊剂工艺制备成胶囊剂。
实施例6
取蝉花子实体粉末10g，加入乳剂(包括微乳、纳米乳等)适当辅料，按乳剂(包括微乳、纳米乳等)工艺制备成乳剂。
实施例7
取蝉花子实体粉末10g，加入颗粒剂适当辅料，按颗粒剂工艺制备成颗粒剂。
实施例8
取蝉花子实体粉末10g，加入缓释控释剂适当辅料，按缓释控释剂工艺制成缓释控释剂。
实施例9
取蝉花子实体粉末10g，加入口服液适当辅料，按口服液工艺制备成口服液。
实施例10
取蝉花子实体粉末10g，加水煎煮两次，每次1小时，合并煎液，过滤，加入注射剂(包括冻干粉针剂和无菌分装干粉针剂)适当辅料，按注射剂(包括冻干粉针剂和无菌分装干粉针剂)工艺制备成注射剂。
实施例11
取蝉花子实体粉末10g，加75％乙醇溶液回流提取两次，每次30分钟，合并提取液，过滤，浓缩后加入片剂(包括缓控释片、骨架片、包衣片、分散片等)适当辅料，按片剂(包括缓控释片、骨架片、包衣片、分散片等)工艺制备成片剂。

Claims (10)

  1. 蝉花子实体在制备治疗痛风的药物中的应用。
  2. 如权利要求1所述的应用，其特征在于，所述痛风包括急性痛风和慢性痛风。
  3. 如权利要求1所述的应用，其特征在于，所述蝉花子实体在制备具有降尿酸作用的药物中的应用。
  4. 如权利要求1所述的应用，其特征在于，所述蝉花子实体在制备治疗痛风引起的肾脏和/或肝脏损害的药物中的应用。
  5. 如权利要求1所述的应用，其特征在于，所述蝉花子实体在制备治疗痛风引起肾小管病变的药物中的应用。
  6. 如权利要求5所述的应用，其特征在于，所述肾小管病变包括肾小管变性、坏死、肾小管扩张或尿酸盐沉积。
  7. 如权利要求1-6任一项所述的应用，其特征在于，所述蝉花子实体为蝉花子实体直接粉碎获得的粉末，或蝉花子实体经常规溶剂提取得到的提取物，或提取物经过精制纯化工艺制备得到的有效部位。
  8. 如权利要求7所述的应用，其特征在于，所述常规溶剂包括水、20％～95％乙醇溶液；所述提取方法包括浸渍提取、超声提取、回流提取、煎煮提取、微波提取、渗漉提取中的任意一种；所述精制纯化工艺包括大孔树脂柱或凝胶柱。
  9. 一种药物组合物，其特征在于，所述组合物包含活性成分蝉花子实体和药学上可接受的辅料。
  10. 如权利要求9所述的药物组合物在制备治疗痛风的药物中的应用。
PCT/CN2018/082483 2017-09-18 2018-04-10 蝉花子实体的新用途 WO2019052165A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710839850.4 2017-09-18
CN201710839850.4A CN109512844A (zh) 2017-09-18 2017-09-18 蝉花子实体的新用途

Publications (1)

Publication Number Publication Date
WO2019052165A1 true WO2019052165A1 (zh) 2019-03-21

Family

ID=65722369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/082483 WO2019052165A1 (zh) 2017-09-18 2018-04-10 蝉花子实体的新用途

Country Status (2)

Country Link
CN (1) CN109512844A (zh)
WO (1) WO2019052165A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1491719A (zh) * 2002-10-25 2004-04-28 上海中医药大学附属龙华医院 蝉花在制备治疗慢性肾功能衰竭的药物中的应用
CN102240301A (zh) * 2010-05-14 2011-11-16 浙江泛亚生物医药股份有限公司 一种单方中药制剂及其制备方法和应用
CN106138115A (zh) * 2016-07-19 2016-11-23 湖州新驰医药科技有限公司 中药材金蝉花的新用途
CN106692208A (zh) * 2015-08-16 2017-05-24 复旦大学 蝉花水提物在制备防治急性肝损伤药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101647951B (zh) * 2009-09-10 2011-12-21 浙江泛亚生物医药股份有限公司 一种中药组合物及其制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1491719A (zh) * 2002-10-25 2004-04-28 上海中医药大学附属龙华医院 蝉花在制备治疗慢性肾功能衰竭的药物中的应用
CN102240301A (zh) * 2010-05-14 2011-11-16 浙江泛亚生物医药股份有限公司 一种单方中药制剂及其制备方法和应用
CN106692208A (zh) * 2015-08-16 2017-05-24 复旦大学 蝉花水提物在制备防治急性肝损伤药物中的用途
CN106138115A (zh) * 2016-07-19 2016-11-23 湖州新驰医药科技有限公司 中药材金蝉花的新用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZHU, RONG ET AL.: "Intervention of Glomerulosclerosis Following 5/6 Nephrectomy by Artificial Cultured Cordyceps Sobolifera Mycelium in Rats", SHANGHAI JOURNAL OF TRADITIONAL CHINESE MEDICINE., vol. 44, no. 05, 10 May 2010 (2010-05-10), XP055583543 *
ZHU, WEIJIAN ET AL.: "Effects of Antinocieptive Compound from Ophiocordyceps Sobolifera on the Transcriptome and Adoral etc. Pain-related Genes in Gouty Rats", MYCOSYSTEMA, vol. 36, no. 01, 22 January 2017 (2017-01-22), pages 48 - 59 *

Also Published As

Publication number Publication date
CN109512844A (zh) 2019-03-26

Similar Documents

Publication Publication Date Title
US10624938B2 (en) Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof
RU2668135C1 (ru) Фармацевтическая композиция для лечения и предотвращения дегенеративных неврологических нарушений, которая содержит, в качестве активного ингредиента, смешанный экстракт коры корня пиона полукустарникового, корня дудника даурского и корня володушки или его фракцию
CN113143997A (zh) 桑提取物在制备减轻动物体重的药物中的应用
CN111568948A (zh) 桑提取物在制备改善胰岛功能药物中的应用
CN109718273B (zh) 紫苏叶提取物在预防或治疗骨性关节炎中的应用
WO2023186181A1 (zh) 桑提取物在制备治疗溃疡性结肠炎的药物中的应用
KR20040032920A (ko) 한입 버섯의 발효 생성물 및 그의 제조 방법과 용도
CN108524668B (zh) 一种对药物性肝损伤具有修复和治疗作用的枸杞提取物的制备方法
WO2019052165A1 (zh) 蝉花子实体的新用途
CN112717031B (zh) 一种用于治疗阿尔茨海默症的药物组合物及其制备方法
CN102028764A (zh) 猫爪草抗结核的有效部位及其制备方法和用途
CN111000924B (zh) 一种具有降血糖作用的中药组合物及其制备方法和应用
CN111840331B (zh) 一种熊胆外泌体在制备治疗ii型糖尿病药物中的应用
CN114869923A (zh) 民族药双参水溶性提取物及其制备方法和应用
CN109568430B (zh) 一种免疫增强剂的制备方法和应用
WO2013138964A1 (zh) 异瑞香新素化合物在制备抗糖尿病药物中的应用
CN114272354B (zh) 用于预防和改善老年痴呆的中药组合物、其制备方法及其应用
CN111450143A (zh) 小叶榕提取物在制备预防和/或治疗肝脏病变的药物中的用途
CN101439069A (zh) 豨莶草叶提取物、其制备方法及其应用
CN112546085A (zh) 一种治疗痛风的接骨草提取物及其制备方法
WO2022188851A1 (zh) 桑提取物在制备减轻动物体重的药物中的应用
CN112022892A (zh) 蓟属植物的有机提取物及其应用与组合物
CN117815261B (zh) 一种锯叶棕果实提取物及其软胶囊的医药新用途
CN116120389B (zh) 人参皂苷Rg5及制备和在制备过敏性鼻炎药物中的应用
WO2024119622A1 (zh) 桑提取物在制备预防和/或治疗肝胆疾病药物中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18855771

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18855771

Country of ref document: EP

Kind code of ref document: A1